Advertisements



We are Sorry, This Page doesn't Exist


Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

Exact Sciences Corp said on Monday it will buy peer Genomic Health Inc for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers......»»

Category: topSource: reutersJul 29th, 2019

Raven (RAVN) Poised to Grow on Investments Amid Cost Woes

New innovation investments, higher oil prices and greater operational efficacy to benefit Raven (RAVN). However, lower prices for agricultural products and escalating cost remain drags. Raven Industries, Inc.’s RA.....»»

Category: smallbizSource: nytAug 27th, 2018

Kennametal (KMT) to Gain From Restructuring Amid Cost Woes

Kennametal (KMT) is poised to grow on the back of solid end-market sales and strategic restructuring moves. However, escalating cost and rising debt burden remain key causes of concern. On Oct 11, we issued an updated research report on .....»»

Category: worldSource: nytOct 11th, 2018

Genomic Health reports results from multiple studies of Oncotype cancer tests

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2018

Here are the retail chains closing amid coronavirus

Retail chains face a big decision amid the coronavirus outbreak -- stay open and risk their employees' health, or close and risk cutting into already thin profit margins. This week several chains announced changes and closures as restrictions grow .....»»

Category: topSource: bizjournalsMar 17th, 2020

New state target would cut health care cost growth in half

A statewide task force has rendered its decision on how fast health care costs should grow in Oregon. At its Wednesday meeting, the Health Care Cost Growth Target Implementation Committee landed on 3.4 percent growth, roughly in line with gross state.....»»

Category: topSource: bizjournalsFeb 13th, 2020

My husband and I put off writing our will after both surviving cancer, but it was a relief to finally write it online for free

Rowan Jordan/Getty Images After a few intense conversations, it took my husband and me less than 15 minutes and cost us nothing to create a will online. Fabric made the process easy — the only hard part was making the decisions. Health iss.....»»

Category: topSource: businessinsiderJan 3rd, 2020

Mailing your poop may seem like an alternative to a colonoscopy, but it could cost you

If your insurance pays for a colorectal cancer screening, be aware that tests like Cologuard could preclude full coverage of a fol.....»»

Category: topSource: usatodayDec 17th, 2019

Mailing your poop may seem like an alternative to a colonoscopy. But it could cost you.

If your insurance pays for a colorectal cancer screening, be aware that tests like Cologuard could preclude full coverage of a fol.....»»

Category: topSource: usatodayDec 17th, 2019

Why Zuckerberg says Facebook likely won"t grow more in the Bay Area

From the high cost of housing to maddening traffic woes, the Bay Area's problems are no secret. And now Mark Zuckerberg, CEO of one of the region's most important companies, says those issues will likely keep Facebook from growing here. Zuckerber.....»»

Category: topSource: bizjournalsOct 4th, 2019

Why Zuckerberg says Facebook likely won"t grow more in the Bay Area

From the high cost of housing to maddening traffic woes, the Bay Area's problems are no secret. And now Mark Zuckerberg, CEO of one of the region's most important companies, says those issues will likely keep Facebook from growing here. Zuckerber.....»»

Category: topSource: bizjournalsOct 4th, 2019

Philadelphia diagnostics disruptor teams up with Lehigh Valley firm for clinical trial

A Philadelphia biotechnology company that is out to transform how patients get diagnostic tests has formed a partnership with a Lehigh Valley-based laboratory services provider. Under the collaboration, Group K Diagnostics and Health Network Laborator.....»»

Category: topSource: bizjournalsAug 22nd, 2019

CVS Health Banks on Health Care Benefit Prospects Amid Woes

On Aug 13 we issued a.....»»

Category: futuresSource: nasdaqAug 14th, 2019

Acquisition Boosts Exact Sciences’ Role in Cancer Diagnostics

Purchase of Genomic Health expands testing capabilities and R&DRelated Stocks: EXAS, GHDX, A, BDX, TMO, ILMN, ABT,.....»»

Category: personnelSource: nytAug 1st, 2019

Exact Sciences to buy Genomic Health for $2.8 billion

Cancer diagnostics company Exact Sciences Corp said on Monday it will buy healthcare company Genomic Health Inc for about $2.8 billion to bolster its cancer testing business......»»

Category: topSource: reutersJul 29th, 2019

Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg

Cancer diagnostics company Exact Sciences Corp is in advanced negotiations to buy healthcare company Genomic Health Inc for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday......»»

Category: topSource: reutersJul 27th, 2019

Astec (ASTE) to Gain From Improving Markets Amid Cost Woes

Astec (ASTE) remains well poised in the long term backed by the global population growth, increased urbanization and the need to repair the ageing.....»»

Category: personnelSource: nytJun 27th, 2019

Study: Health Care Costs Worry Americans More Than Any Other Financial Problem

As the cost of U.S. health care services and medications continue to grow at an alarming pace, Americans are now more likely to cite health care costs at their top financial problem, according to a........»»

Category: blogSource: 247wallstMay 30th, 2019

CVS tests its vitamins and supplements, tosses some that didn"t pass

As CVS Health Corp. tries to grow its prominence in the health and wellness space, it says it's completed third-party testing of vitamins and supplements to prove that they actually contain what they say they do. The Woonsocket, R.I.-based company (N.....»»

Category: topSource: bizjournalsMay 15th, 2019

At-home genetic kits don"t reveal all breast cancer risks

Millions of people have bought into the mail-in DNA testing craze, but a new study indicates consumers should be aware of the limitations of the health tests offered.  Those who expect 23andMe to detect most breast cancer risks are being cautioned.....»»

Category: topSource: bizjournalsApr 19th, 2019